Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02455167 · ClinicalTrials.gov registry record · Phase 3
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
A Phase 3 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT02455167 is a Phase 3 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 9 participants.
The verdict
NCT02455167, a Phase 3 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV). 2. Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT.
Interventions
- DRUG Ribavirin (RBV)
- DRUG Sofosbuvir (SOF)
- DRUG Simeprivir (SMV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-07-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02455167
The ClinicalTrials.gov registry entry for NCT02455167 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin (RBV) is the first listed.
NCT02455167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02455167 about?
NCT02455167 is a clinical study titled "Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis". 1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin (or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV). 2. Hepatic improvement during and after Simeprevir(SMV)/Sofos...
What is the current status of trial NCT02455167?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2015-05. Estimated completion is 2016-07-18.
What interventions are being tested in trial NCT02455167?
The interventions under investigation include: Ribavirin (RBV) (DRUG), Sofosbuvir (SOF) (DRUG), Simeprivir (SMV) (DRUG).
Who is sponsoring clinical trial NCT02455167?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.